Infermedica

Infermedica tackles the problem of inappropriate use of medical services and misdiagnosis, providing insurance companies, hospitals, and health systems with a set of advanced preliminary diagnosis and triage tools, that include products: Symptom Checker, Call Center Triage, Emergency Room Triage, and Medical API.
Founded in 2012 by a team of engineers, data scientists, and physicians, Infermedica develops its diagnostic engine to collect intake, check symptoms, and guide patients to the right care. The technology can also detect emergencies and support healthcare professionals by giving them early access to health information and recommendations.
“The broader goal is to improve customers’ performance, increase healthcare accessibility, and reduce costs. To date, our tools have been used by over 3.5 million users worldwide, and we have signed partnerships with over 30 leading insurance and healthcare companies, including Allianz Partners, Taipei Medical University Hospital, and Everyday Health,” says Piotr Orzechowski, Infermedica’s CEO.
The company uses artificial intelligence and machine learning to assess symptoms and find patterns in data. Thanks to algorithms, Infermedica gets smarter over time. Besides, the team of physicians verifies every piece of information that is added to the medical database to ensure that patients get safe and reliable recommendations. To date, physicians involved in the project have spent 18,000 hours doing the review.
Infermedica’s core product is a symptom checker that allows patients to perform a preliminary diagnostic interview. The AI suggests the most suitable and cost-efficient action to take such as visiting or calling a doctor, self-care treatment, or going to an Emergency Department in case of highly severe symptoms. Infermedica assists patients in making the best decisions regarding their symptoms and at the same time, allows healthcare companies to save money by making sure that patients use the proper services to treat their health issues.
In the past year, Infermedica has grown its staff to more than 70 people. Also, its products were translated into 15 languages, making them available in such countries as China and the United Arab Emirates.
To learn more, visit infermedica.com and check showcase application Symptomate, available both for mobile and web on symptomate.com.
2012
Piotr Orzechowski (CEO), Dr. Irv Loh, MD (Chief Medical Officer), Roberto Sicconi (Chief Science Officer)
70
3650000
At ExecInsurtech we are looking for
EXECinsurtech is one of Europe’s leading conferences focusing on technological innovation in the insurance industry. Infermedica’s technology has been successfully helping insurance companies enhance patient outcomes and reduce costs, which allows them to strengthen their market position. We want to present our solutions to the people involved in the process of developing the future of the insurance industry to inspire them.
Our Plans for 2020
Infermedica wants to strengthen its presence in the U.S and Europe and accelerate the development of its technology. Further plans for 2020 include making available for market use the pediatric dataset as well as closing the Series A.
What makes YOUR COMPANY special?
– 93% diagnostic engine accuracy
The accuracy of our technology has been confirmed by cases from BMJ, NEJM, JAMA, and others
– 3,500,000+ health checkups
Every day, people rely on information provided by Infermedica to find the right care.
Read More ...
– We work with the best
Infermedica helps to enhance outcomes for Allianz Partners, Dôvera, Everyday Health, Health Loop, Médis, PZU Zdrowie, and more!
– 15 languages and counting
A doctor and a patient don’t have to speak the same language! You can translate the interview results immediately, in just one click.
– CE marking
The solution is marked as a CE class 1 certified medical device.
– EU-GDPR
Compliant with the General Data Protection Regulation (GDPR).
– Easy to integrate and customizable
Integrate our solution into tools you already use, such as websites, mobile apps, or telehealth platforms.
Show Less